Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan ter Meulen

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Vaccine|August 24, 2020
ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalitiesJardin A Leleux, Tina C Albershardt, Andrea J Parsons, et al.
Proteins|April 30, 2013
In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutininV Vamsee Aditya Mallajosyula, Michael Citron, Xianghan Lu, et al.
Virology|May 28, 2005
Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variantsStephane Daffis, Roland E Kontermann, Jehanara Korimbocus, et al.
NPJ Vaccines|June 25, 2020
Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumorsTina C Albershardt, Jardin Leleux, Andrea J Parsons, et al.
Journal of Virology|September 13, 2003
Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]Thomas Strecker, Robert Eichler, Jan ter Meulen, et al.
The Journal of Infectious Diseases|March 2, 2010
Serological evidence of human hantavirus infections in Guinea, West AfricaBoris Klempa, Lamine Koivogui, Oumar Sylla, et al.
Molecular Therapy Oncolytics|September 15, 2016
LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune responseTina Chang Albershardt, David James Campbell, Andrea Jean Parsons, et al.
Vaccine|August 15, 2013
Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaquesDaniel DiStefano, Joseph M Antonello, Andrew J Bett, et al.
Journal of Virology|November 21, 2014
Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challengeChristine Meyer, Flora Engelmann, Nicole Arnold, et al.
Virus Research|March 17, 2004
Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP)Robert Eichler, Thomas Strecker, Larissa Kolesnikova, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Vaccine|August 24, 2020
ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalitiesJardin A Leleux, Tina C Albershardt, Andrea J Parsons, et al.
Proteins|April 30, 2013
In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutininV Vamsee Aditya Mallajosyula, Michael Citron, Xianghan Lu, et al.
Virology|May 28, 2005
Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variantsStephane Daffis, Roland E Kontermann, Jehanara Korimbocus, et al.
NPJ Vaccines|June 25, 2020
Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumorsTina C Albershardt, Jardin Leleux, Andrea J Parsons, et al.
Journal of Virology|September 13, 2003
Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]Thomas Strecker, Robert Eichler, Jan ter Meulen, et al.
The Journal of Infectious Diseases|March 2, 2010
Serological evidence of human hantavirus infections in Guinea, West AfricaBoris Klempa, Lamine Koivogui, Oumar Sylla, et al.
Molecular Therapy Oncolytics|September 15, 2016
LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune responseTina Chang Albershardt, David James Campbell, Andrea Jean Parsons, et al.
Vaccine|August 15, 2013
Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaquesDaniel DiStefano, Joseph M Antonello, Andrew J Bett, et al.
Journal of Virology|November 21, 2014
Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challengeChristine Meyer, Flora Engelmann, Nicole Arnold, et al.
Virus Research|March 17, 2004
Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP)Robert Eichler, Thomas Strecker, Larissa Kolesnikova, et al.
Pageof 6